Want to see TSE:VXL full AI Analyst Report?
VXL Stock Chart & Stats
C$0.16
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.16
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.13 - C$0.29
Previous CloseN/A
Volume0.00
Average Volume (3M)1.63K
Market Cap
C$597.60K
Enterprise ValueC$0.25
Total Cash (Recent Filing)C$464.00K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)1.5
Beta-0.98
Next Earnings
Nov 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding3,984,020
10 Day Avg. Volume2,861
30 Day Avg. Volume1,632
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.30
Price to Sales (P/S)0.00
P/FCF Ratio-2.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetA debt-free balance sheet reduces mandatory interest payments and refinancing exposure, giving the company greater financial flexibility while it remains in development. This is a durable structural advantage because it lowers solvency pressure even though operating losses and cash burn continue.
Positive Equity BalancePositive equity provides a stronger balance-sheet foundation than a deficit position and indicates that liabilities have not exceeded the company’s recorded assets. Although equity has fluctuated materially, maintaining a positive balance supports resilience as Vaxil continues its clinical-stage development activities.
Improving Cash BurnThe reduction in cash burn versus earlier periods suggests some improvement in cash usage, even though the business is not yet self-funding. If sustained, better cash discipline could extend financial runway and make development spending more manageable over the next several quarters.
Bears Say
No Reported RevenueThe absence of reported revenue shows that Vaxil has not yet demonstrated recurring commercial traction from its biotechnology activities. This leaves the business dependent on development progress and future monetization rather than established product demand, making financial performance difficult to sustain organically.
Persistent Operating LossesNegative EBIT across every reported period indicates that the core business remains structurally unprofitable. Until operating activities generate positive earnings, any improvement in reported net income is unlikely to demonstrate durable operating progress, and continued development will remain financially demanding.
Negative Operating Cash FlowPersistent negative operating and free cash flow means the company is not generating enough cash internally to fund its activities. The mismatch between positive net income in 2025 and TTM and negative operating cash flow also raises earnings-quality concerns because reported profits are not converting into cash.
Vaxil Bio News
VXL FAQ
What was Vaxil Bio Ltd’s price range in the past 12 months?
Vaxil Bio Ltd lowest stock price was C$0.13 and its highest was C$0.29 in the past 12 months.
What is Vaxil Bio Ltd’s market cap?
Vaxil Bio Ltd’s market cap is C$597.60K.
When is Vaxil Bio Ltd’s upcoming earnings report date?
Vaxil Bio Ltd’s upcoming earnings report date is Nov 25, 2026 which is in 62 days.
How were Vaxil Bio Ltd’s earnings last quarter?
Vaxil Bio Ltd released its earnings results on Aug 24, 2026. The company reported -C$0.016 earnings per share for the quarter.
Is Vaxil Bio Ltd overvalued?
According to Wall Street analysts Vaxil Bio Ltd’s price is currently Overvalued.
Does Vaxil Bio Ltd pay dividends?
Vaxil Bio Ltd does not currently pay dividends.
What is Vaxil Bio Ltd’s EPS estimate?
Vaxil Bio Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaxil Bio Ltd have?
Vaxil Bio Ltd has 3,984,020 shares outstanding.
What happened to Vaxil Bio Ltd’s price movement after its last earnings report?
Vaxil Bio Ltd reported an EPS of -C$0.016 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vaxil Bio Ltd?
Currently, no hedge funds are holding shares in TSE:VXL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vaxil Bio Ltd
Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.
Technical Analysis
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Defence Therapeutics
―